ATE320803T1 - Verfahren zur behandlung von alzheimerschen krankheit - Google Patents
Verfahren zur behandlung von alzheimerschen krankheitInfo
- Publication number
- ATE320803T1 ATE320803T1 AT98960605T AT98960605T ATE320803T1 AT E320803 T1 ATE320803 T1 AT E320803T1 AT 98960605 T AT98960605 T AT 98960605T AT 98960605 T AT98960605 T AT 98960605T AT E320803 T1 ATE320803 T1 AT E320803T1
- Authority
- AT
- Austria
- Prior art keywords
- disease
- treating alzheimer
- lowering agent
- alzheimer
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7291298P | 1998-01-28 | 1998-01-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE320803T1 true ATE320803T1 (de) | 2006-04-15 |
Family
ID=22110517
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT98960605T ATE320803T1 (de) | 1998-01-28 | 1998-12-02 | Verfahren zur behandlung von alzheimerschen krankheit |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1051161B1 (de) |
JP (1) | JP2002501887A (de) |
KR (2) | KR20010034417A (de) |
AT (1) | ATE320803T1 (de) |
AU (1) | AU762124B2 (de) |
BR (1) | BR9814923A (de) |
CA (1) | CA2311356C (de) |
DE (1) | DE69833971T2 (de) |
ES (1) | ES2257824T3 (de) |
NZ (1) | NZ505761A (de) |
WO (1) | WO1999038498A1 (de) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6080778A (en) * | 1998-03-23 | 2000-06-27 | Children's Medical Center Corporation | Methods for decreasing beta amyloid protein |
US6472421B1 (en) | 1998-11-13 | 2002-10-29 | Nymox Corporation | Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor |
NZ518822A (en) * | 1999-11-04 | 2004-12-24 | Andrx Corp | Treating a mammal with an APP processing disorder such as Alzheimer's Disease and Down's Syndrome by administering at least one HMG-CoA reductase inhibitor |
US20010028895A1 (en) * | 2000-02-04 | 2001-10-11 | Bisgaier Charles L. | Methods of treating alzheimer's disease |
AU2001263003A1 (en) * | 2000-06-07 | 2001-12-17 | Warner Lambert Company | Carboxyalkylether-acat inhibitor combinations |
EP1911462A3 (de) | 2001-01-26 | 2011-11-30 | Schering Corporation | Zusammensetzungen enthaltend einen Sterolabsorptionshemmer |
CA2437480A1 (en) * | 2001-02-05 | 2002-08-15 | Andrx Corporation | Method of treating amyloid .beta. precursor disorder |
EP1370210A4 (de) * | 2001-02-07 | 2004-08-18 | Mclean Hospital Corp | Cholesterinsenkende mittel als behandlung gegen psychische und kognitive störungen |
ATE345792T1 (de) * | 2001-05-25 | 2006-12-15 | Schering Corp | Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer- krankheit |
JP2004002365A (ja) * | 2002-04-05 | 2004-01-08 | Sankyo Co Ltd | Acat阻害剤とインシュリン抵抗性改善剤とからなる医薬組成物 |
AU2003236365A1 (en) * | 2002-04-05 | 2003-10-20 | Sankyo Company, Limited | Medicinal composition comprising acat inhibitor and insuline resistance improving agent |
FR2848452B1 (fr) * | 2002-12-12 | 2007-04-06 | Aventis Pharma Sa | Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer |
US7393826B2 (en) | 2003-07-03 | 2008-07-01 | Lipid Sciences, Inc. | Methods and apparatus for creating particle derivatives of HDL with reduced lipid content |
WO2005011620A2 (en) * | 2003-07-03 | 2005-02-10 | Lipid Sciences Inc. | Methods and apparatus for creating particle derivatives of hdl with reduced lipid content |
EP1918000A2 (de) | 2003-11-05 | 2008-05-07 | Schering Corporation | Verbindungen aus lipidverändernden Wirkstoffen und substituierten Azetidinonen und Behandlungen für Gefäßzustände |
ES2435790T3 (es) | 2004-12-03 | 2013-12-23 | Intervet International B.V. | Piperazinas sustituidas como antagonistas de CB1 |
CA2592320C (en) | 2004-12-22 | 2015-11-24 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
US8324276B2 (en) | 2005-01-24 | 2012-12-04 | Pronova Biopharma Norge As | Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction |
US8372886B2 (en) | 2005-12-22 | 2013-02-12 | Kiacta Sarl | Treatment of renal disorders, diabetic nephropathy and dyslipidemias |
CA2637565A1 (en) | 2006-01-18 | 2007-07-26 | Schering Corporation | Cannibinoid receptor modulators |
PL3851447T3 (pl) | 2006-10-12 | 2024-03-04 | Bellus Health Inc. | Sposoby, związki, kompozycje i nośniki dostarczające kwas 3-amino-1-propanosulfonowy |
BRPI0814806A2 (pt) | 2007-06-28 | 2015-02-03 | Intervet Int Bv | Pirazinas substituídas como antagonistas de cb1 |
US20140370011A1 (en) * | 2009-06-04 | 2014-12-18 | Dara Biosciences, Inc. | Methods of treating or preventing cognitive impairment using indane acetic acid derivatives |
US20180200230A1 (en) * | 2009-06-04 | 2018-07-19 | Dara Biosciences, Inc. | Methods of treating neurodegenerative diseases using indane acetic acid derivatives which penetrate the blood brain barrier |
EP4238566A1 (de) | 2012-05-02 | 2023-09-06 | Georgetown University | Behandlung der Amyotrophen Lateralsklerose mit Tyrosinkinasehemmern |
WO2015042286A1 (en) * | 2013-09-18 | 2015-03-26 | Georgetown University | Treating neurodegenerative disease with fenofibrate and analogs thereof |
FR3014694B1 (fr) * | 2013-12-13 | 2016-11-11 | Roquette Freres | Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl |
EP3220906B1 (de) | 2014-11-19 | 2022-03-02 | Rush University Medical Center | Zusammensetzungen und verfahren zur behandlung lysosomaler störungen |
US11027052B2 (en) | 2017-11-22 | 2021-06-08 | HDL Therapuetics, Inc. | Systems and methods for priming fluid circuits of a plasma processing system |
JP2021509894A (ja) | 2017-12-28 | 2021-04-08 | エイチディーエル セラピューティクス インコーポレイテッドHdl Therapeutics, Inc. | ヒト血漿から抽出されたpre−β高密度リポタンパク質を保存および投与するための方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5248785A (en) * | 1990-02-12 | 1993-09-28 | Virginia Commonwealth University | Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood |
WO1995006470A1 (en) * | 1993-08-30 | 1995-03-09 | Merck & Co., Inc. | Prevention and treatment of alzheimer's disease |
JPH08143454A (ja) * | 1994-11-17 | 1996-06-04 | Kanagawa Kagaku Kenkyusho:Kk | 神経成長因子産生増強剤 |
US5648387A (en) * | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
GB9611947D0 (en) * | 1996-06-07 | 1996-08-07 | Glaxo Group Ltd | Medicaments |
US5965553A (en) * | 1996-06-20 | 1999-10-12 | Pfizer Inc. | Squalene synthetase inhibitors |
WO1997048701A1 (en) * | 1996-06-20 | 1997-12-24 | Pfizer Inc. | 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors |
SK285210B6 (sk) * | 1996-10-11 | 2006-09-07 | Scarista Limited | Farmaceutický prípravok na liečenie schizofrénie a použitie oleja obsahujúceho kyselinu eikozapentaenovú alebo stearidonovú, alebo ich kombináciu na prípravu tohto liečiva |
EP1006794B1 (de) * | 1997-03-12 | 2007-11-28 | Robert W. Esmond | Verfahren zur behandlung oder prävention der alzheimerischen krankheit |
DE19716120A1 (de) * | 1997-04-17 | 1998-10-22 | Europ Lab Molekularbiolog | Verwendung von cholesterinsenkenden Mitteln |
-
1998
- 1998-12-02 JP JP2000529231A patent/JP2002501887A/ja active Pending
- 1998-12-02 WO PCT/US1998/025495 patent/WO1999038498A1/en not_active Application Discontinuation
- 1998-12-02 BR BR9814923-7A patent/BR9814923A/pt not_active Application Discontinuation
- 1998-12-02 ES ES98960605T patent/ES2257824T3/es not_active Expired - Lifetime
- 1998-12-02 DE DE69833971T patent/DE69833971T2/de not_active Expired - Fee Related
- 1998-12-02 KR KR1020007008187A patent/KR20010034417A/ko not_active Application Discontinuation
- 1998-12-02 NZ NZ505761A patent/NZ505761A/en unknown
- 1998-12-02 EP EP98960605A patent/EP1051161B1/de not_active Expired - Lifetime
- 1998-12-02 AU AU16165/99A patent/AU762124B2/en not_active Ceased
- 1998-12-02 AT AT98960605T patent/ATE320803T1/de not_active IP Right Cessation
- 1998-12-02 KR KR1020067000221A patent/KR100592842B1/ko not_active IP Right Cessation
- 1998-12-02 CA CA002311356A patent/CA2311356C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
NZ505761A (en) | 2003-08-29 |
JP2002501887A (ja) | 2002-01-22 |
AU1616599A (en) | 1999-08-16 |
ES2257824T3 (es) | 2006-08-01 |
CA2311356A1 (en) | 1999-08-05 |
WO1999038498A1 (en) | 1999-08-05 |
EP1051161B1 (de) | 2006-03-22 |
BR9814923A (pt) | 2000-10-17 |
KR20060009409A (ko) | 2006-01-31 |
EP1051161A1 (de) | 2000-11-15 |
AU762124B2 (en) | 2003-06-19 |
DE69833971D1 (de) | 2006-05-11 |
CA2311356C (en) | 2004-07-13 |
DE69833971T2 (de) | 2006-11-02 |
KR100592842B1 (ko) | 2006-06-26 |
KR20010034417A (ko) | 2001-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE320803T1 (de) | Verfahren zur behandlung von alzheimerschen krankheit | |
DE60126980D1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
ATE218854T1 (de) | Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase | |
DE69521700D1 (de) | Mittel und methoden zur behandlung von plaque-krankheiten | |
ATE390142T1 (de) | Synergistische zusammensetzung zur behandlung von diabetes mellitus | |
GB0225474D0 (en) | Therapeutic agents | |
DE60239612D1 (de) | Monodisperse mischungen und verfahren zur behandlung von diabetes | |
ATE417602T1 (de) | Mittel zur behandlung von erkrankungen der speiseröhre | |
DE69925024D1 (de) | Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten | |
ATE396174T1 (de) | Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
ATE412646T1 (de) | Zur behandlung von schmerzen geeignete therapeutische mittel | |
WO2001058476A3 (en) | Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity | |
BG105302A (en) | Means for improving cognition | |
FI972703A0 (fi) | Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia | |
WO2002094189A3 (en) | Compositions and methods for treating or preventing convulsions or seizures | |
DE69935853D1 (de) | Anwendung von alfa1beta1 integrinrezeptorinhibitoren und tgf-beta1-inhibitoren zur behandlung von nierenkrankheiten | |
ATE415163T1 (de) | Verfahren und zusammensetzungen zur behandlung von augenerkrankungen | |
RS50148B (sr) | Upotreba docetaksela za lečenje hepatoćelijskog karcinoma | |
DE69936994D1 (de) | Verfahren zur behandlung von okularen neovaskularen erkrankungen | |
DK1189627T3 (da) | Sammensætninger indeholdende opløselige former af HLA-G til behandling af inflammatoriske patologiske tilstande i huden | |
PT1237562E (pt) | Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas | |
TR200200278T2 (tr) | Kalsilitik bileşimler | |
DE69733169D1 (de) | Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs | |
DE60144493D1 (de) | Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen | |
ATE344662T1 (de) | Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |